Cite
APA Citation
Goess, C., Harris, C. M., Murdock, S., McCarthy, R. W., Sampson, E., Twomey, R., Mathieu, S., Mario, R., Perham, M., Goedken, E. R., & Long, A. J. (2019). aBBV-105, a selective and irreversible inhibitor of Bruton's tyrosine kinase, is efficacious in multiple preclinical models of inflammation. Modern rheumatology, 29(3), 510–522. http://access.bl.uk/ark:/81055/vdc_100081440679.0x00003b